A Phase 1, Open-Label, Dose-Escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-Positive Refractory/Relapsed Hodgkin's Lymphoma.

Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-Positive Refractory/Relapsed Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs MDX 1401 (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Planned end date changed from 1 Aug 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 26 Mar 2009 Interim results will be presented at the American Association for Cancer Research annual meeting (AACR-2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top